BioSpace News Archive

Simulations Plus, Inc. (Nasdaq: SLP) announced today that it will report financial results for the first quarter of fiscal year 2023, the period ended November 30, 2022, after the close of the financial markets on Wednesday, January 4, 2023.

Invitae, a leading medical genetics company, announced the appointment by the U.S. Government Accountability Office of Deven McGraw, lead of data stewardship and data sharing at Invitae, to the National Health Information Technology Advisory Committee.

Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today broadly shared two poster presentations initially released at the 2022 San Antonio Breast Cancer Symposium (SABCS).

Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) approval of the company’s Eterna™ spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain.

CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced today positive top-line safety, tolerability and proof of concept data, with early efficacy benefit, in a Phase 2 clinical trial with CST-103 in patients with Parkinson’s disease (PD) or mild cognitive impairment (MCI).

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform, is announcing the expansion of its global agreement with Novo Nordisk for the commercialization of Dose Check.

n-Lorem, a nonprofit foundation, announced today that four investigational new drug (IND) applications have been filed successfully with the FDA and n-Lorem has begun dosing on three nano-rare patients. n-Lorem anticipates dosing the fourth patient in early 2023.

Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company, today announced a clinical trial collaboration and supply agreement.

Invectys, Inc. and CTMC today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors.

Cothera Bioscience today announced that it has dosed the first patient with PC-002, a first-in-class deubiquitinase (DUB) inhibitor, in a global multi-center phase 2 clinical trial for the treatment of high-grade B-cell lymphoma with Myc rearrangement (NCT05263583).